{"id":876314,"date":"2025-08-15T12:09:15","date_gmt":"2025-08-15T16:09:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/"},"modified":"2025-08-15T12:09:15","modified_gmt":"2025-08-15T16:09:15","slug":"berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/","title":{"rendered":"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n PHILADELPHIA<\/span>
\n <\/span>, Aug. 15, 2025<\/span><\/span> \/PRNewswire\/ — Berger Montague PC<\/span><\/a><\/u>\u00a0is investigating potential securities fraud<\/span> claims on behalf of investors of\u00a0Altimmune, Inc. (NASDAQ: ALT) <\/b>(“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between\u00a0August 10, 2023<\/span> through June 25, 2025<\/span><\/b>(the “Class Period”).<\/p>\n

\n

\n
\n \"A
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n Investor Deadline:<\/i>
\n <\/b>
\n \u00a0Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025<\/span><\/b>, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,<\/i>\u00a0CLICK HERE<\/a><\/u><\/b>.<\/b><\/p>\n

Altimmune, headquartered in Gaithersburg, Maryland<\/span>, is a\u00a0clinical-stage biopharmaceutical company.<\/p>\n

The lawsuit alleges<\/span> that on June 26, 2025<\/span>, Altimmune announced that\u00a0its IMPACT study had failed to achieve statistical significance in the trial’s primary endpoint of fibrosis reduction, citing a\u00a0higher-than-expected placebo response. Despite management’s prior optimistic statements, the Company downplayed the poor results, attributing the outcome to the Phase 2 nature of the trial and suggesting improvements in a future Phase 3 study.<\/p>\n

Following this disclosure, Altimmune’s stock\u00a0plunged 53%<\/i><\/b>, from\u00a0a close of $7.71<\/span> per share on June 25, 2025<\/span>, to a close of $3.61<\/span> on June 26, 2025<\/span>, causing heavy losses for investors.<\/p>\n

\n
\n If you are an Altimmune investor and would like to learn more about this action, <\/i>
\n <\/b>
\n
\n
\n
\n CLICK HERE<\/a>
\n <\/u>
\n <\/i>
\n <\/b>\u00a0or please contact Berger Montague<\/span>: Andrew Abramowitz<\/span> at <\/i><\/b>aabramowitz@bergermontague.com<\/a><\/u><\/i><\/b> or (215) 875-3015, or Caitlin Adorni<\/span> at <\/i><\/b>cadorni@bergermontague.com<\/a><\/u><\/i><\/b> or (267)764-4865.<\/i><\/b><\/p>\n

\n About Berger Montague<\/span>
<\/b>
\n Berger Montague<\/span>, with offices in Philadelphia<\/span>, Minneapolis<\/span>, Delaware<\/span>, Washington, D.C.<\/span>, San Diego<\/span>, San Francisco<\/span>, Chicago<\/span>, Malvern, PA<\/span>, and Toronto<\/span> has been a pioneer in securities class action litigation<\/a><\/u>\u00a0since its founding in 1970. Berger Montague<\/span> has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States<\/span>.<\/p>\n

\n For more information or to discuss your rights, please contact:
<\/b>
\n Andrew Abramowitz<\/span>, Senior Counsel
Berger Montague<\/span>
(215) 875-3015
aabramowitz@bergermontague.com<\/a><\/p>\n

\n Caitlin Adorni<\/span>
\n
\n Berger Montague<\/span>
\n
(267) 764-4865
cadorni@bergermontague.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt-302530712.html<\/a><\/p>\n

SOURCE Berger Montague<\/span><\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire PHILADELPHIA , Aug. 15, 2025 \/PRNewswire\/ — Berger Montague PC\u00a0is investigating potential securities fraud claims on behalf of investors of\u00a0Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between\u00a0August 10, 2023 through June 25, 2025(the “Class Period”). Investor Deadline: \u00a0Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. Altimmune, headquartered in Gaithersburg, Maryland, is a\u00a0clinical-stage biopharmaceutical company. The lawsuit alleges that on June 26, 2025, Altimmune announced that\u00a0its IMPACT study had failed … <\/p>\n

Continue reading “Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-876314","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBerger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA , Aug. 15, 2025 \/PRNewswire\/ — Berger Montague PC\u00a0is investigating potential securities fraud claims on behalf of investors of\u00a0Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between\u00a0August 10, 2023 through June 25, 2025(the “Class Period”). Investor Deadline: \u00a0Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. Altimmune, headquartered in Gaithersburg, Maryland, is a\u00a0clinical-stage biopharmaceutical company. The lawsuit alleges that on June 26, 2025, Altimmune announced that\u00a0its IMPACT study had failed … Continue reading "Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T16:09:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)\",\"datePublished\":\"2025-08-15T16:09:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/\"},\"wordCount\":340,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/\",\"name\":\"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"datePublished\":\"2025-08-15T16:09:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/","og_locale":"en_US","og_type":"article","og_title":"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA , Aug. 15, 2025 \/PRNewswire\/ — Berger Montague PC\u00a0is investigating potential securities fraud claims on behalf of investors of\u00a0Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between\u00a0August 10, 2023 through June 25, 2025(the “Class Period”). Investor Deadline: \u00a0Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. Altimmune, headquartered in Gaithersburg, Maryland, is a\u00a0clinical-stage biopharmaceutical company. The lawsuit alleges that on June 26, 2025, Altimmune announced that\u00a0its IMPACT study had failed … Continue reading \"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-15T16:09:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)","datePublished":"2025-08-15T16:09:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/"},"wordCount":340,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/","name":"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","datePublished":"2025-08-15T16:09:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-securities-claims-against-altimmune-inc-nasdaq-alt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=876314"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876314\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=876314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=876314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=876314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}